<h4>Introduction/background</h4>The C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index is a new prognostic biomarker combining CRP, serum albumin, and lymphocyte count that can be associated with the survival of cancer patients by assessing immune, nutritional, and inflammatory status as an important immune indicator. The gene discussed is CRP; the disease is cancer.